Form 4: Collegium Pharma EVP Sells Shares

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, executed a pre-planned sale of 4,861 common shares following an option exercise.

Summary

• Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, Inc. (COLL), engaged in transactions on August 13, 2025.
• Exercised stock options to acquire 4,861 shares of common stock at an exercise price of $21.34 per share.
• Simultaneously sold 4,861 shares of common stock at a weighted average price of $38.0335 per share.
• The sales occurred within a price range of $38.00 to $38.10 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Scott Dreyer directly owns 103,613 shares of common stock and 16,389 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine Form 4 filing disclosing an insider's pre-planned option exercise and share sale, which is a common compensation-related activity and does not inherently indicate positive or negative company performance or outlook.

Positives

• The option exercise price of $21.34 is significantly lower than the sale price of $38.0335, indicating a profitable transaction for the insider.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned, non-discretionary sale and reduces concerns about opportunistic insider trading.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction for an executive in the pharmaceutical industry. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction. The exercise of options and subsequent sale of shares is a common practice for executives to realize compensation and manage personal finances. There are no specific comparable companies or projects mentioned in the filing itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and share ownership changes.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Collegium Pharmaceutical, COLL, Scott Dreyer, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Pharmaceuticals